Myo-Inositol

SKU
02177-250C
/ NPN: 80108036
Dairy Free Gluten Free GMO Free Vegan Vegetarian
Your Price CA$56.75
Retail Price
CA$56.75

Healthcare Practitioners

Exclusive Benefits

Healthcare Practitioners receive:

  • Access to practitioner pricing
  • Special offers & promotions
  • Brochures & supporting materials
Set Up an Account Sign In

Non-Practitioners

How To Buy
Support for ovarian health
  • Aids in the management of polycystic ovarian syndrome (PCOS) by helping to restore normal ovarian function
  • Aids in the management of PCOS’s hormonal and metabolic conditions by promoting healthy glucose metabolism
  • Aids in the management of PCOS by reducing oxidative stresses
  • Helps to restore ovulation and oocyte quality and to normalize menstrual cycle irregularities
  • Helps to reduce serum testosterone in women with PCOS

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting up to 20% of women of reproductive age.1 PCOS is associated with elevated male sex hormones, impaired insulin sensitivity and reproductive dysfunction, including menstrual irregularity and infertility.1 Myo-inositol helps restore the activities of ovaries in PCOS patients through its role as a precursor to inositol 1,4,5-triphosphate (InsP3), which regulates menstrual cycle hormones and oocyte maturation.3,4 Myo-inositol also promotes the production of inositolphosphoglycans (IPG), which activate enzymes involved in glucose metabolism.3 In a clinical trial involving 42 women with PCOS, participants were randomized to consume 400 mcg of folic acid alone or in combination with 4 g of myo-inositol daily for six to eight weeks.5 When compared to the placebo folic acid group, women in the myo-inositol group experienced more cycles of ovulation (69.5% ovulated in the myo-inositol group compared with 21% in the placebo group), lower testosterone levels, and improved insulin sensitivity.5

REFERENCES
1. Misso M, Boyle J, Norman R, Teede H. Semin Reprod Med. 2014 May;32(3):230–40.
2. Carlomagno G, Unfer V. Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):931-6.
3. Unfer V, Carlomagno G, Dante G, Facchinetti F. Gynecol Endocrinol. 2012 Jul;28(7): 509–15.
4. Govindarajan C, Pitchaipillai R, Shanmugasundaram B, Thangam S, Arokiasamy J, Pillai MS. World J Pharm Pharm Sci. 2015;4(6):137-55.
5. Costantino D, Minozzi G, Minozzi, E, Guaraldi C. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.